Does Ozempic Work? 2025 Research Data on Peptide Efficacy & Market Trends
Does Ozempic Work? 2025 Research Data on Peptide Efficacy & Market Trends Current 2025 research confirms that semaglutide, the active peptide in Ozempic, demonstrates high efficacy for glycemic control and weight management, driving a 14.2% CAGR in the peptide market. While GLP-1 receptor agonists dominate, industry analysis reveals a shift toward next-generation dual/triple agonists (e.g., tirzepatide) offering superior metabolic benefits. Peptide technology advantages include high target specificity and low toxicity, though limitations like oral bioavailability and stability persist. Brand competition intensifies between Novo Nordisk and Eli Lilly, with factory GMP certifications and product COAs becoming critical differentiators. Applications now extend beyond diabetes to cardiovascular, NASH, and neurodegenerative disorders. Manufacturers must prioritize ISO 22716 compliance and third-party purity testing to validate peptide quality in this rapidly expanding sector.